Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 62
Filter
1.
Int J Rheum Dis ; 27(5): e15166, 2024 May.
Article in English | MEDLINE | ID: mdl-38720417

ABSTRACT

OBJECTIVES: To identify the effectiveness and safety of inactivated SARS-CoV-2 vaccines in rheumatic and musculoskeletal diseases (RMDs) patients. METHODS: RMD patients with COVID-19 in Jiangsu Province were polled between December 8, 2022, and February 1, 2023. Information on demographics, disease characteristics, antirheumatic drug use, vaccination status and survival state were collected. COVID-19-associated pneumonia was the primary outcome. The effect of COVID-19 immunization on RMD patients was assessed using multivariate logistic regression, and the adverse events (AEs) following vaccination were evaluated. RESULTS: Among 592 RMD patients with COVID-19, 276 (46.6%) individuals experienced COVID-19-associated pneumonia, and 290 (49.0%) patients were injected with inactivated vaccines. In multivariate logistic regression analysis, vaccines reduced the incidence of COVID-19-associated pneumonia, and receiving booster vaccine was an independent protective factor for COVID-19-associated pneumonia in RMD patients (OR 0.64, 95% CI 0.41-0.98, p = .034). In particular, inactivated vaccines have a protective impact on RMD patients with a high risk of developing pneumonia, including those aged 45 years and older (OR 0.53, 95% CI 0.34-0.83), and who have lung involvement (OR 0.43, 95% CI 0.23-0.82). The total AEs rate of vaccines was 13.9% (40/290), only 11 (3.8%) experienced the recurrence or deterioration of RMDs, and no serious AEs occurred. CONCLUSION: Inactivated COVID-19 vaccines were safe and effective in reducing the risk of COVID-19-associated pneumonia of RMD patients in China.


Subject(s)
COVID-19 Vaccines , COVID-19 , Musculoskeletal Diseases , Rheumatic Diseases , Vaccines, Inactivated , Humans , COVID-19/prevention & control , COVID-19/epidemiology , Rheumatic Diseases/immunology , Rheumatic Diseases/drug therapy , Rheumatic Diseases/epidemiology , Male , Female , Middle Aged , Retrospective Studies , COVID-19 Vaccines/adverse effects , COVID-19 Vaccines/administration & dosage , Musculoskeletal Diseases/diagnosis , Musculoskeletal Diseases/epidemiology , Vaccines, Inactivated/adverse effects , Aged , Adult , SARS-CoV-2/immunology , China/epidemiology , Vaccine Efficacy , Treatment Outcome , Risk Factors
2.
Sci Rep ; 14(1): 11443, 2024 May 20.
Article in English | MEDLINE | ID: mdl-38769384

ABSTRACT

Electrochromic devices are applied extensively to camouflages, smart windows, heat insulation layers, and automobile rearview mirrors, etc. The amorphous WO3 is a very attractive electrochromic material, whereas it suffers from degradation of optical modulation and reversibility on ion exchange owing to those deep trapped ions with irreversible reaction behavior. Herein, we designed and, by using magnetron sputtering, prepared a composite film with TiO2/WO3/TiO2 double heterojunctions, which is capable of eliminating the deep trapped ions by itself under ultraviolet light (UV) assistance. The electrochromic device based on this composite film, after being recovery by short-time UV irradiation, can maintain a high transmission modulation of 94.72% after 7000 cycles of the voltammetry measurement. This feature allows the device to maintain its initial electrochromic performance after prolonged use. Moreover, the double heterojunction structure can reduce colouring time and enormously improve the colouration efficiency (CE) of electrochromic devices. Experimental research shows that when the thickness of the bottom and upper TiO2 layer of the WO3 film was 145.5 nm and 97.0 nm, respectively, the CE of electrochromic devices reached a perfectly high value (479.3 cm2/C), being much higher than that of WO3 devices (69.5 cm2/C). Functions of the TiO2/WO3/TiO2 double heterojunction in electrochromic device were investigated by combining theoretical analysis and experiment validation, and these results provide a general framework for developing and designing superior electrochromic materials and devices.

3.
Int J Rheum Dis ; 27(4): e15131, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38563679

ABSTRACT

OBJECTIVE: To evaluate the incidence and associated factors of initial and recurrent severe infections in hospitalized patients with systemic lupus erythematosus (SLE). METHODS: SLE patients that first hospitalized between 2010 and 2021 were studied retrospectively and divided into SLE with and without baseline severe infection groups. The primary outcome was the occurrence of severe infection during follow-up. Cox regression models were used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for initial and recurrent severe infections. RESULTS: Among 1051 first hospitalized SLE patients, 164 (15.6%) had severe infection on admission. During a median follow-up of 4.1 years, 113 (10.8%) patients reached severe infection outcomes, including 27 with reinfection and 86 with initial severe infection (16.5% vs. 9.7%, p = .010). Patients with baseline severe infection had a higher cumulative incidence of reinfection (p = .007). After adjusting for confounding factors, renal involvement, elevated serum creatinine, hypoalbuminemia, cyclophosphamide, and mycophenolate mofetil treatment were associated with an increased risk of severe infection, especially initial severe infection. Low immunoglobulin, anti-dsDNA antibody positivity, and cyclophosphamide use significantly increased the risk of recurrent severe infection, with adjusted HR (95% CI) of 3.15 (1.22, 8.14), 3.60 (1.56, 8.28), and 2.14 (1.01, 5.76), respectively. Moreover, baseline severe infection and low immunoglobulin had a multiplicative interaction on reinfection, with adjusted RHR (95% CI) of 3.91 (1.27, 12.09). CONCLUSION: In this cohort of SLE, patients with severe infection had a higher risk of reinfection, and low immunoglobulin, anti-dsDNA antibody positivity, and cyclophosphamide use were independent risk factors for recurrent severe infection.


Subject(s)
Lupus Erythematosus, Systemic , Reinfection , Humans , Retrospective Studies , Cyclophosphamide/adverse effects , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/epidemiology , Risk Factors , Immunoglobulins , China/epidemiology
4.
RMD Open ; 10(2)2024 Apr 24.
Article in English | MEDLINE | ID: mdl-38663883

ABSTRACT

OBJECTIVES: Risk prediction for patients with polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD) is challenging due to heterogeneity in the disease course. We aimed to develop a mortality risk prediction model for PM/DM-ILD. METHODS: This prognostic study analysed patients with PM/DM-ILD admitted to Nanjing Drum Hospital from 2016 to 2021. The primary outcome was mortality within 1 year. We used a least absolute shrinkage and selection operator (LASSO) logistic regression model to identify predictive laboratory indicators. These indicators were used to create a laboratory risk score, and we developed a mortality risk prediction model by incorporating clinical factors. The evaluation of model performance encompassed discrimination, calibration, clinical utility and practical application for risk prediction and prognosis. RESULTS: Overall, 418 patients with PM/DM-ILD were enrolled and randomly divided into development (n=282) and validation (n=136) cohorts. LASSO logistic regression identified four optimal features in the development cohort, forming a laboratory risk score: C reactive protein, lactate dehydrogenase, CD3+CD4+ T cell counts and PO2/FiO2. The final prediction model integrated age, arthralgia, anti-melanoma differentiation-associated gene 5 antibody status, high-resolution CT pattern and the laboratory risk score. The prediction model exhibited robust discrimination (area under the receiver operating characteristic: 0.869, 95% CI 0.811 to 0.910), excellent calibration and valuable clinical utility. Patients were categorised into three risk groups with distinct mortality rates. The internal validation, sensitivity analyses and comparative assessments against previous models further confirmed the robustness of the prediction model. CONCLUSIONS: We developed and validated an evidence-based mortality risk prediction model with simple, readily accessible clinical variables in patients with PM/DM-ILD, which may inform clinical decision-making.


Subject(s)
Dermatomyositis , Lung Diseases, Interstitial , Humans , Lung Diseases, Interstitial/mortality , Lung Diseases, Interstitial/etiology , Lung Diseases, Interstitial/diagnosis , Lung Diseases, Interstitial/complications , Male , Female , Middle Aged , Dermatomyositis/complications , Dermatomyositis/mortality , Dermatomyositis/diagnosis , Risk Assessment , Prognosis , Aged , Adult , Risk Factors , Logistic Models , Polymyositis/complications , Polymyositis/mortality , Polymyositis/diagnosis , ROC Curve
5.
Spectrochim Acta A Mol Biomol Spectrosc ; 312: 124048, 2024 May 05.
Article in English | MEDLINE | ID: mdl-38387412

ABSTRACT

Due to the acidic tumor microenvironment caused by metabolic changes in tumor cells, the accurate pH detection of extracellular fluid is helpful for doctors in precise tumor resection. The combination of Raman spectroscopy and deep learning provides a solution for pH detection. However, most existing studies use one-dimensional convolutional neural networks (1D-CNNs) for spectral analysis, which limits the performance due to insufficient feature extraction. In this work, we propose a 2D triple-branch feature fusion network (TriFNet) for accurate pH determination using surface-enhanced Raman spectra (SERS). Specifically, we design a triple-branch network structure by converting Raman spectra into three types of images to extensively extract complex patterns in spectra. In addition, an attention fusion module, which leverages the complementarity among features in both space and channel, is designed to obtain the valuable information, achieving further accurate pH determination. On our Raman spectral dataset containing 14,137 samples, we achieved mean absolute error (MAE) of 0.059, standard deviation of the absolute error (SD) of 0.07, root mean squared error (RMSE) of 0.092, and coefficient of determination (R2) of 0.991 on the test set. Compared with other published methods, the four metrics showed an average improvement of 47%, 39%, 43%, and 6%, respectively. In addition, visualization validates the diagnostic capability of our model to correlate with biomolecular signatures. Meanwhile, our model has robustness to different SERS chips. These results prove the potential of our method to develop an effective technology based on Raman spectroscopy for accurate pH determination to guide surgery.


Subject(s)
Benchmarking , Spectrum Analysis, Raman , Extracellular Fluid , Neural Networks, Computer , Hydrogen-Ion Concentration
6.
Int J Comput Assist Radiol Surg ; 19(4): 677-686, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38289466

ABSTRACT

PURPOSE: Stereo matching is a crucial technology in the binocular laparoscopic-based surgical navigation systems. In recent years, neural networks have been widely applied to stereo matching and demonstrated outstanding performance. however, this method heavily relies on manual feature engineering meaning that professionals must be involved in the feature extraction and matching. This process is both time-consuming and demands specific expertise. METHODS: This paper introduces a novel stereo matching framework DCStereo that realizes a fully automatic neural architecture design for the stereo matching of binocular laparoscopic images. The proposed framework utilizes a densely connected search space which enables a more flexible and diverse architecture composition. Furthermore, the proposed algorithm leverages the channel and path sampling strategies to reduce memory consumption during searching. RESULTS: Empirically, our searched DCStereo on the SCARED training dataset achieves a mean absolute error of 3.589 mm on the test dataset, which outperforms hand-crafted stereo matching methods and other approaches. Furthermore, when directly testing on the SERV-CT dataset, our DCStereo demonstrates better generalization ability than other methods. CONCLUSION: Our proposed approach leverages the neural architecture search technique and a densely connected search space for automatic neural architecture design in stereo matching of binocular laparoscopic images. Our method delivers advanced performance on the SCARED dataset and promising results on the SERV-CT dataset. These findings demonstrate the potential of our approach for improving clinical surgical navigation systems.


Subject(s)
Algorithms , Laparoscopy , Humans , Neural Networks, Computer
7.
J Magn Reson Imaging ; 2024 Jan 18.
Article in English | MEDLINE | ID: mdl-38236785

ABSTRACT

BACKGROUND: Quantitative in-situ pH mapping of gliomas is important for therapeutic interventions, given its significant association with tumor progression, invasion, and metastasis. Although chemical exchange saturation transfer (CEST) offers a noninvasive way for pH imaging based on the pH-dependent exchange rate (ksw ), the reliable quantification of ksw in glioma remains constrained due to technical challenges. PURPOSE: To quantify the pH of gliomas by measuring the proton exchange rate through optimized omega plot analysis. STUDY TYPE: Prospective. PHANTOMS/ANIMAL MODEL/SUBJECTS: Creatine and murine brain lysates phantoms, six rats with glioma xenograft model, and three patients with World Health Organization grade 2-4 gliomas. FIELD STRENGTH/SEQUENCE: 11.7 T, 7.0 T, CEST imaging, T2 -weighted (T2 W) imaging, and T1 -mapping. ASSESSMENT: Omega plot analysis, quasi-steady-state (QUASS) analysis, multi-pool Lorentzian fitting, amine and amide concentration-independent detection, pH enhanced method with the combination of amide and guanidyl (pHenh ), and magnetization transfer ratio (MTR) were utilized for pH metric quantification. The clinical outcomes were determined through radiologic follow-up and histopathological analysis. STATISTICAL TESTS: Mann-Whitney U test was performed to compare glioma with normal tissue, and Pearson's correlation analysis was used to assess the relationship between ksw and other parameters. RESULTS: In vitro experiments reveal that the determined ksw at 2 ppm increases exponentially with pH (creatine phantoms: ksw = 106 + 0.147 × 10(pH-4.198) ; lysates: ksw = 185.1 + 0.101 × 10(pH-3.914) ). Omega plot analysis exhibits a linear correlation between 1/MTRRex and 1/ω1 2 in the glioma xenografts (R2 > 0.98) and glioma patients (R2 > 0.99). The exchange rate in the rat glioma decreases compared to the contralateral normal tissue (349.46 ± 30.40 s-1 vs. 403.54 ± 51.01 s-1 , P = 0.025), while keeping independence from changes in concentration (r = 0.5037, P = 0.095). Similar pattern was observed in human data. DATA CONCLUSION: Utilizing QUASS-based, spillover-, and MT-corrected omega plot analysis for the measurement of exchange rates, offers a feasible method for quantifying pH within glioma. LEVEL OF EVIDENCE: NA TECHNICAL EFFICACY: Stage 1.

8.
Sci Rep ; 14(1): 2032, 2024 01 23.
Article in English | MEDLINE | ID: mdl-38263232

ABSTRACT

Polyps are well-known cancer precursors identified by colonoscopy. However, variability in their size, appearance, and location makes the detection of polyps challenging. Moreover, colonoscopy surveillance and removal of polyps are highly operator-dependent procedures and occur in a highly complex organ topology. There exists a high missed detection rate and incomplete removal of colonic polyps. To assist in clinical procedures and reduce missed rates, automated methods for detecting and segmenting polyps using machine learning have been achieved in past years. However, the major drawback in most of these methods is their ability to generalise to out-of-sample unseen datasets from different centres, populations, modalities, and acquisition systems. To test this hypothesis rigorously, we, together with expert gastroenterologists, curated a multi-centre and multi-population dataset acquired from six different colonoscopy systems and challenged the computational expert teams to develop robust automated detection and segmentation methods in a crowd-sourcing Endoscopic computer vision challenge. This work put forward rigorous generalisability tests and assesses the usability of devised deep learning methods in dynamic and actual clinical colonoscopy procedures. We analyse the results of four top performing teams for the detection task and five top performing teams for the segmentation task. Our analyses demonstrate that the top-ranking teams concentrated mainly on accuracy over the real-time performance required for clinical applicability. We further dissect the devised methods and provide an experiment-based hypothesis that reveals the need for improved generalisability to tackle diversity present in multi-centre datasets and routine clinical procedures.


Subject(s)
Crowdsourcing , Deep Learning , Polyps , Humans , Colonoscopy , Computers
9.
Sci Rep ; 13(1): 21655, 2023 12 08.
Article in English | MEDLINE | ID: mdl-38066207

ABSTRACT

Colorectal cancer is a leading cause of cancer-related deaths globally. In recent years, the use of convolutional neural networks in computer-aided diagnosis (CAD) has facilitated simpler detection of early lesions like polyps during real-time colonoscopy. However, the majority of existing techniques require a large training dataset annotated by experienced experts. To alleviate the laborious task of image annotation and utilize the vast amounts of readily available unlabeled colonoscopy data to further improve the polyp detection ability, this study proposed a novel self-supervised representation learning method called feature pyramid siamese networks (FPSiam). First, a feature pyramid encoder module was proposed to effectively extract and fuse both local and global feature representations among colonoscopic images, which is important for dense prediction tasks like polyp detection. Next, a self-supervised visual feature representation containing the general feature of colonoscopic images is learned by the siamese networks. Finally, the feature representation will be transferred to the downstream colorectal polyp detection task. A total of 103 videos (861,400 frames), 100 videos (24,789 frames), and 60 videos (15,397 frames) in the LDPolypVideo dataset are used to pre-train, train, and test the performance of the proposed FPSiam and its counterparts, respectively. The experimental results have illustrated that our FPSiam approach obtains the optimal capability, which is better than that of other state-of-the-art self-supervised learning methods and is also higher than the method based on transfer learning by 2.3 mAP and 3.6 mAP for two typical detectors. In conclusion, FPSiam provides a cost-efficient solution for developing colorectal polyp detection systems, especially in conditions where only a small fraction of the dataset is labeled while the majority remains unlabeled. Besides, it also brings fresh perspectives into other endoscopic image analysis tasks.


Subject(s)
Colonic Polyps , Humans , Colonic Polyps/diagnostic imaging , Colonic Polyps/pathology , Colonoscopy/methods , Neural Networks, Computer , Diagnosis, Computer-Assisted/methods , Image Processing, Computer-Assisted
10.
Opt Express ; 31(24): 39681-39694, 2023 Nov 20.
Article in English | MEDLINE | ID: mdl-38041284

ABSTRACT

To meet the requirements of time-frequency networks and enable frequency downloadability for nodes along the link, we demonstrated the extraction of stable frequency signals at nodes using a mode-locked laser under the condition of 100 km laboratory fiber. The node consists of a simple structure that utilizes widely used optoelectronic devices and enables plug-and-play applications. In addition, the node can recover frequency signals with multiple frequencies, which are useful for scenarios that require different frequencies. Here, we experimentally demonstrated a short-term frequency instability of 2.83 × 10-13@1 s and a long-term frequency instability of 1.18 × 10-15@10,000 s at the node, which is similar to that at the remote site of the frequency transfer system. At the same time, frequency signals with different frequencies also achieved stable extraction with the same performance at the node. Our results can support the distributed application under large-scale time-frequency networks.

11.
Lupus Sci Med ; 10(2)2023 11 22.
Article in English | MEDLINE | ID: mdl-37993281

ABSTRACT

OBJECTIVES: The study aims to investigate the impact of gene polymorphisms on blood hydroxychloroquine (HCQ) concentrations in patients with SLE and provide guidelines for individualised care. METHODS: 489 Chinese patients with SLE taking HCQ for more than 3 months were collected in this study. The blood HCQ, desethylhydroxychloroquine (DHCQ) and desethylchloroquine concentrations were measured. The optimal blood concentration of HCQ was determined by receiver operating characteristic curve analysis. Single nucleotide polymorphisms of metabolic enzymes involved in HCQ metabolism were genotyped and the associations with treatment effects were investigated. RESULTS: The cut-off value of HCQ was 559.67 ng/mL, with sensitivity and specificity values of 0.51 and 0.89, respectively. The TC and CC genotypes of CYP2C8 (rs7910936) were significantly related to the increase in blood HCQ concentrations, and the CYP2C8 (rs10882521) TT genotype was associated with lower blood HCQ concentrations. The DHCQ:HCQ ratio was highest in patients with the GG genotype of the CYP2D6*10 (rs1065852) polymorphism and lowest in those with the AA genotype. Patients with the CYP2C8 (rs7910936) CC genotype were more likely to achieve the optimal blood concentration (p=0.030) in HCQ 200 mg/day group and patients with the CYP2D6*10 (rs1065852) GG genotype were more likely to reach the optimal blood concentration (p=0.049) in 400 mg/day group. CONCLUSIONS: Our results suggest that the optimal blood concentration of HCQ measured approximately 12-18 hours after the last dosage may be between 500 and 600 ng/mL in Chinese patients with SLE. The observed variations in HCQ concentrations between individuals can potentially be attributed to genetic polymorphisms in CYP2D6*10 (rs1065852) and CYP2C8 (rs7910936 and rs10882521). Genotypical testing of patients and regular monitoring of blood levels are recommended for optimising HCQ dosage management in Chinese patients with SLE. TRIAL REGISTRATION NUMBER: ChiCTR2300070628.


Subject(s)
Antirheumatic Agents , Lupus Erythematosus, Systemic , Humans , Hydroxychloroquine/therapeutic use , Antirheumatic Agents/therapeutic use , Cytochrome P-450 CYP2C8 , Cytochrome P-450 CYP2D6/genetics , East Asian People , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/genetics , Genotype
12.
RMD Open ; 9(4)2023 11 23.
Article in English | MEDLINE | ID: mdl-37996129

ABSTRACT

OBJECTIVE: Patients with systemic lupus erythematosus (SLE) have an increased risk of venous thromboembolism (VTE). We conducted this study to develop a risk score algorithm for VTE in patients with SLE that provides individualised risk estimates. METHODS: We developed a clinical prediction model of VTE in 4502 patients with SLE based on the Chinese SLE Treatment and Research group cohort (CSTAR) from January 2009 to January 2020 and externally validated in 3780 patients with SLE in CSTAR from January 2020 to January 2022. Baseline data were obtained and VTE events were recorded during the follow-up. The prediction model was developed to predict VTE risk within 6 months in patients with SLE, using multivariate logistic regression and least absolute shrinkage and selection operator. SLE-VTE score and nomogram were established according to the model. RESULTS: A total of 4502 patients included in the development cohort, 135 had VTE events. The final prediction model (SLE-VTE score) included 11 variables: gender, age, body mass index, hyperlipidaemia, hypoalbuminaemia, C reactive protein, anti-ß2GPI antibodies, lupus anticoagulant, renal involvement, nervous system involvement and hydroxychloroquine, with area under the curve of 0.947 and 0.808 in the development (n=4502) and external validation cohort (n=3780), respectively. According to the net benefit and predicted probability thresholds, we recommend annual screening of VTE in high risk (≥1.03%) patients with SLE. CONCLUSION: Various factors are related to the occurrence of VTE in patients with SLE. The proposed SLE-VTE risk score can accurately predict the risk of VTE and help identify patients with SLE with a high risk of VTE who may benefit from thromboprophylaxis.


Subject(s)
Lupus Erythematosus, Systemic , Venous Thromboembolism , Venous Thrombosis , Humans , Venous Thromboembolism/diagnosis , Venous Thromboembolism/epidemiology , Venous Thromboembolism/etiology , Venous Thrombosis/epidemiology , Venous Thrombosis/etiology , Anticoagulants , Models, Statistical , Prognosis , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/epidemiology
13.
BMC Pulm Med ; 23(1): 356, 2023 Sep 22.
Article in English | MEDLINE | ID: mdl-37737172

ABSTRACT

BACKGROUND: Rheumatoid arthritis (RA) is a major public health problem. Unfortunately, there is a scarcity of comprehensive and up-to-date information regarding the burden of RA and its dynamic trends in subsequent years. To examine the changing trends in the global burden of RA and forecast for 2044, which will facilitate the development of strategies tailored to RA burden and provide reference for the development of effective treatment guidelines. METHODS: Following the general analytical strategy used the Global Burden of Disease Study (GBD) 2019, which included 204 countries, the age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR) and age-standardized disability adjusted of life year (DALY) rate for RA were analyzed. RESULTS: The ASIR, ASMR and age-standardized DALY rate for RA in 2019 were 13.001/100,000 (95% UI, 11.833 ~ 14.274), 0.574/100,000 (95% UI, 0.356 ~ 0.793) and 39.565/100,000 (95% UI, 49.529 ~ 30.508), respectively. America had the highest ASIR [18.578(95% UI, 17.147 ~ 20.148)] and age-standardized DALY rate [53.676(95% UI, 40.106 ~ 67.968)] in 2019. Asia had the highest ASMR [0.681(95% UI, 0.802 ~ 0.480)] in 2019. From 1990 to 2019, a significant average annual percentage change (AAPC) in the ASIR was observed in both males [0.237% (95% CI, 0.216 ~ 0.259%)] and females [0.197% (95% CI, 0.141 ~ 0.254%)], AAPC in the ASMR was observed in both males [-0.398% (95% CI, -0.605~-0.191%)] and females [-0.295% (95% CI, -0.424~-0.65%)]. Age effects indicated that the relative risk (RR) of RA-associated incidence and mortality rates increased with age among males and females. The RR of RA increased over time and started to gradually increase from 1990. Cohort effects showed decreases in incidence, mortality and DALY rates in successive birth cohorts. The global incidence of RA would continue to increase in the future, while mortality would continue to decrease. CONCLUSION: The increased risk of RA is dominantly influenced by age effects and period effects and the ethnic area. The results suggest that early identification and treatment of RA is important for reducing the ongoing burden with age, and targeted health education and specific intervention programs should be promoted to control middle-elderly population.


Subject(s)
Arthritis, Rheumatoid , Female , Male , Humans , Aged , Incidence , Arthritis, Rheumatoid/epidemiology , Health Education , Cohort Studies
14.
Rheumatol Ther ; 10(6): 1535-1554, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37742321

ABSTRACT

INTRODUCTION: The association between mycophenolate mofetil (MMF) and infection in patients with systemic lupus erythematosus (SLE) has not been clarified. This study evaluated the degree and factors in effect of MMF use on infection in patients with SLE. METHODS: A hospitalized-based observational study was conducted to collect medical records on patients with SLE during 2010-2021. A nested case-control study was performed among 3339 patients with SLE, including 1577 cases and 1762 controls by whether they developed any type of infection. The exposure of MMF use was determined within 1 year before diagnosed infection or the end of follow-up. Logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (CI) for association between MMF and subsequent infection. RESULTS: MMF was significantly associated with the risk of overall infection (adjusted OR 1.90, 95% CI 1.48-2.44) and different types of infections, including bacterial infection (adjusted OR 2.07, 95% CI 1.55-2.75), viral infection (adjusted OR 1.92, 95% CI 1.23-3.01), and opportunistic infection (adjusted OR 2.13, 95% CI 1.31-3.46). The top three risks of specific types of infections were bacteremia/septicemia, urinary tract infection/pyelonephritis, and herpes zoster. Stratification analysis showed risk of overall infection increased especially in MMF users with age over 55 years, diabetes, central nervous system involvement, and thrombocytopenia. Moreover, the risk of infection increased with increasing dosage and duration of MMF use. Additionally, the combination of MMF with CYC and other immunosuppressants significantly increases the risk of infections compared to using a single one. CONCLUSIONS: MMF use is associated with various type of infections in patients with SLE, particularly in those with longer use, older age, complications with comorbidities, and concomitant use of CYC or other immunosuppressants.

15.
Rheumatol Int ; 2023 Sep 26.
Article in English | MEDLINE | ID: mdl-37750894

ABSTRACT

We aimed to investigate the factors associated with vitamin D deficiency and changes in 25 (OH)D levels, as well as the impact of those changes on disease activity and renal function among SLE patients. This retrospective cohort study was based on the medical records of SLE patients hospitalized between 2010 and 2021. We collected relevant information from this patient population. Logistic regression analysis was employed to determine the factors associated with vitamin D deficiency and increased 25 (OH)D levels, and we calculated the odds ratios (ORs) and 95% confidence intervals (CIs) accordingly. At baseline, among the 1257 SLE patients, the median and interquartile range of 25 (OH)D levels were 14 (9, 20) ng/ml, with 953 (75.8%) patients exhibiting 25 (OH)D deficiency (< 20 ng/ml). The presence of 25 (OH)D deficiency was found to be associated with renal involvement and a high glucocorticoid (GC) maintenance dose. Among the 383 patients who were followed up for an average of 18 months, an increase of at least 100% in 25 (OH)D levels was positively associated with a decreased GC maintenance dose and vitamin D3 supplementation, with adjusted odds ratios(OR) (95% confidence interval [CI]) of 2.16 (1.02, 4.59) and 1300 (70, 22300), respectively. Furthermore, an increased level of 25 (OH)D was significantly associated with a decrease in the Disease Activity Index 2000 score and the urinary protein/creatinine ratio. Patients with SLE have low vitamin D levels, especially those with impaired kidney function. Increased 25 (OH)D levels can be achieved through supplementation with high doses of vitamin D3 and are associated with improvements in disease activity and the urinary protein/creatinine ratio.

16.
J Appl Clin Med Phys ; 24(8): e14084, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37430473

ABSTRACT

Retrograde intrarenal surgery (RIRS) is a widely utilized diagnostic and therapeutic tool for multiple upper urinary tract pathologies. The image-guided navigation system can assist the surgeon to perform precise surgery by providing the relative position between the lesion and the instrument after the intraoperative image is registered with the preoperative model. However, due to the structural complexity and diversity of multi-branched organs such as kidneys, bronchi, etc., the consistency of the intensity distribution of virtual and real images will be challenged, which makes the classical pure intensity registration method prone to bias and random results in a wide search domain. In this paper, we propose a structural feature similarity-based method combined with a semantic style transfer network, which significantly improves the registration accuracy when the initial state deviation is obvious. Furthermore, multi-view constraints are introduced to compensate for the collapse of spatial depth information and improve the robustness of the algorithm. Experimental studies were conducted on two models generated from patient data to evaluate the performance of the method and competing algorithms. The proposed method obtains mean target error (mTRE) of 0.971 ± 0.585 mm and 1.266 ± 0.416 mm respectively, with better accuracy and robustness overall. Experimental results demonstrate that the proposed method has the potential to be applied to RIRS and extended to other organs with similar structures.


Subject(s)
Algorithms , Imaging, Three-Dimensional , Humans , Imaging, Three-Dimensional/methods , Phantoms, Imaging
17.
Stem Cells Transl Med ; 12(7): 431-443, 2023 Jul 14.
Article in English | MEDLINE | ID: mdl-37279956

ABSTRACT

OBJECTIVES: Mesenchymal stromal cells (MSCs) and low-dose interleukin-2 (IL-2) both have demonstrated efficacy in treating systemic lupus erythematosus (SLE). The aim of this study is to conduct a head-to-head comparison between the 2 treatments and provide insights for clinical applications. METHODS: Lupus-prone mice were treated with umbilical cord-derived MSCs (UC-MSCs), IL-2, or a combination of UC-MSCs and IL-2, respectively. The lupus-like symptoms, renal pathology, and T-cell response were assessed 1 or 4 weeks later. Modulation of IL-2 production by MSCs on immune cells was investigated by the coculture assay. Disease activity and serum IL-2 of SLE patients were determined before and after receiving UC-MSCs. RESULTS: Both UC-MSCs and IL-2 improved lupus symptoms in lupus-prone mice 1 week after treatment, while the effects of UC-MSCs lasted up to 4 weeks. Moreover, the UC-MSC-treated group showed better renal pathology improvement. Importantly, UC-MSCs combined with IL-2 did not provide better efficacy than UC-MSCs alone. Consistent with this, UC-MSCs alone and UC-MSCs + IL-2 resulted in similar levels of serum IL-2 and frequencies of Tregs. Neutralization of IL-2 partly reduced the promotion of Tregs by UC-MSCs, suggesting that IL-2 was involved in the upregulation of Tregs by UC-MSCs. Lastly, an increase in serum IL-2 positively correlated with the reduction of disease activity of SLE patients by UC-MSCs. CONCLUSION: Both the single injection of UC-MSCs and repeated IL-2 administration exerted comparable efficacy in alleviating SLE manifestations, but UC-MSCs provided sustained alleviation and showed better improvement in renal pathology.


Subject(s)
Lupus Erythematosus, Systemic , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells , Animals , Mice , Interleukin-2/pharmacology , Lupus Erythematosus, Systemic/therapy , Coculture Techniques , Umbilical Cord , Mesenchymal Stem Cell Transplantation/methods
18.
J Clin Med ; 12(3)2023 Jan 30.
Article in English | MEDLINE | ID: mdl-36769709

ABSTRACT

To explore the etiology of risk factors and quantify the mortality differences in systemic lupus erythematosus (SLE) patients with different initial disease activity. The Jiangsu Lupus database was established by collecting medical records from first-hospitalized SLE patients during 1999-2009 from 26 centers in Jiangsu province, China, and their survival status every five years. The initial SLEDAI scores [high (>12) vs. low-moderate (≤12)] differences in mortality attributable to risk factors were quantified using population attributable fraction (PAF), relative attributable risk (RAR) and adjusted relative risk (ARR). Among 2446 SLE patients, 83 and 176 deaths were observed in the low-moderate and high activity groups, with mortality rates of 7.7 and 14.0 per 1000 person years, respectively. Anemia was the leading contributor to mortality, with PAFs of 40.4 and 37.5 in the low-moderate and high activity groups, respectively, and explained 23.2% of the mortality differences with an ARR of 1.66 between the two groups. Cardiopulmonary involvement caused the highest PAFs in the low-moderate (20.5%) and high activity (13.6%) groups, explaining 18.3% of the mortality differences. The combination of anemia and cardiopulmonary involvement had the highest RAR, causing 39.8% of the mortality differences (ARR = 1.52) between the two groups. In addition, hypoalbuminemia and a decrease in the creatinine clearance rate accounted for 20-30% of deaths and explained 10-20% of the mortality differences between the two groups, while antimalarial drug nonuse accounted for about 35% of deaths and explained 3.6% of the mortality differences. Anemia, cardiopulmonary involvement and hypoalbuminemia may cause substantial mortality differences across disease activity states, suggesting additional strategies beyond disease activity assessment to monitor SLE outcomes.

19.
Biochem Biophys Res Commun ; 650: 87-95, 2023 04 02.
Article in English | MEDLINE | ID: mdl-36791546

ABSTRACT

Abnormal infiltration and activation of neutrophils play a pathogenic role in the development of lupus nephritis (LN). Myeloid-related proteins (MRPs), MRP-8 and -14, also known as the damage-associated molecular patterns (DAMPs), are mainly secreted by activated neutrophils in systemic lupus erythematosus (SLE). Mesenchymal stem cells (MSCs) regulate a variety of immune cells to treat LN, but it is not clear whether MSCs can regulate neutrophils and the expression of MRP-8/14 in LN. Here, we demonstrated that neutrophil infiltration and MRP-8/14 expression were increased in the kidney of MRL/lpr mice and both decreased after MSCs transplantation. Further, the results showed that tumor necrosis factor- (TNF) stimulated gene-6 (TSG-6) in MSCs is necessary for MSCs to inhibit MRP-8/14 expression in neutrophils and neutrophil migration. In addition, small-molecule immunosuppressant had no significant effect on the expression of MRP-8/14 in neutrophils. Therefore, our results suggest that MSCs inhibited MRP-8/14 expression and neutrophil migration by secreting TSG-6 in the treatment of LN.


Subject(s)
Lupus Erythematosus, Systemic , Lupus Nephritis , Mesenchymal Stem Cells , Mice , Animals , Lupus Nephritis/pathology , Neutrophils/metabolism , Mice, Inbred MRL lpr , Lupus Erythematosus, Systemic/pathology
20.
Brain ; 146(6): 2275-2284, 2023 06 01.
Article in English | MEDLINE | ID: mdl-36730056

ABSTRACT

Tau accumulation in patients with Alzheimer's disease tracks closely with cognitive decline and plays a role in the later stages of disease progression. This phase 2 study evaluated the safety and efficacy of tilavonemab, an anti-tau monoclonal antibody, in patients with early Alzheimer's disease. In this 96-week, randomized, double-blind, placebo-controlled study (NCT02880956), patients aged 55-85 years meeting clinical criteria for early Alzheimer's disease with a Clinical Dementia Rating-Global Score of 0.5, a Mini-Mental State Examination score of 22 to 30, a Repeatable Battery for the Assessment of Neuropsychological Status-Delayed Memory Index score of ≤85, and a positive amyloid PET scan were randomized 1:1:1:1 to receive one of three doses of tilavonemab (300 mg, 1000 mg, or 2000 mg) or placebo via intravenous infusion every 4 weeks. The primary end point was the change from baseline up to Week 96 in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score. Safety evaluations included adverse event monitoring and MRI assessments. A total of 453 patients were randomized, of whom 337 were treated with tilavonemab (300 mg, n = 108; 1000 mg, n = 116; 2000 mg, n = 113) and 116 received placebo. Baseline demographics and disease characteristics were comparable across groups. The mean age was 71.3 (SD 7.0) years, 51.7% were female, and 96.5% were White. At baseline, the mean CDR-SB score was 3.0 (1.2), which worsened through Week 96 for all treatment groups. The least squares mean change from baseline at Week 96 in the CDR-SB score with tilavonemab was not significantly different compared with placebo [300 mg (n = 85): -0.07 (95% confidence interval, CI: -0.83 to 0.69); 1000 mg (n = 91): -0.06 (95% CI: -0.81 to 0.68); 2000 mg (n = 81): 0.16 (95% CI: -0.60 to 0.93); all P ≥ 0.05]. The incidence of any adverse event and MRI findings were generally comparable across groups. Tilavonemab was generally well tolerated but did not demonstrate efficacy in treating patients with early Alzheimer's disease. Further investigations of tilavonemab in early Alzheimer's disease are not warranted.


Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Humans , Female , Aged , Male , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/drug therapy , Alzheimer Disease/psychology , Double-Blind Method , Positron-Emission Tomography , Magnetic Resonance Imaging , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...